Close Menu

diabetes

While the Lab 2.0 vision is still in its early days, a number of outfits around the country are providing examples of how it might be implemented.

The grant will support the development of a high-throughput method to extract and test dried blood samples collected by patients at home.

The Finnish biotechnology firm also announced plans to raise up to €80 million in the coming year.

The firm said that a new R&D plant will enable it to develop non-core testing applications that allow it to enter new markets, such as veterinary diagnostics.

The firm is conducting clinical trials in preparation for applying for FDA clearance to market its POC instrument and first assay in the first quarter of next year.

The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.

The firm said it anticipates launching the platform in Europe next year and completing its first round of external financing in the first quarter of 2020.

The mass spec test is designed to measure blood-based proteins to predict type 2 diabetes patients' risk of developing diabetic kidney disease.

The FDA cleared the system, comprising a blood collection device and associated test to measure long-term glucose levels in patients with diabetes. 

Agilent has partnered with the National University of Singapore and National University Hospital to establish the S$38 million ($27.4 million) research and development facility in Singapore.

Pages